Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience

References

• Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–4086.
   PubMed Web of Science ®Google Scholar
• Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006;12(4):438–453.
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhang R, Wang H, et al. Comparison of outcomes of idarubicin intensified TBI-CY and traditional TBI-CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: a single center experience. Leuk Res. 2015;39(11):1192–1200.
   Web of Science ®Google Scholar
• Toubai T, Tanaka J, Mori A, et al. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies. Clin Transplant. 2004;18(5):552–557.
   PubMed Web of Science ®Google Scholar
• Imamura M, Shigematsu A. Perspectives on the use of a medium-dose etoposide, cyclophosphamide, and total body irradiation conditioning regimen in allogeneic hematopoietic stem cell transplantation: the Japanese experience from 1993 to present. J Clin Med. 2019;8(5):599.
   Web of Science ®Google Scholar
• Mori T, Aisa Y, Kato J, et al. Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Am J Hematol. 2012;87(4):349–353.
   PubMed Web of Science ®Google Scholar
• Paix A, Antoni D, Waissi W, et al. Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: a review. Crit Rev Oncol Hematol. 2018;123:138–148.
   PubMed Web of Science ®Google Scholar
• Gooptu M, Kim HT, Ho VT, et al. A comparison of the myeloablative conditioning regimen fludarabine/busulfan with cyclophosphamide/total body irradiation, for allogeneic stem cell transplantation in the modern era: a cohort analysis. Biol Blood Marrow Transplant. 2018;24(8):1733–1740.
   PubMed Web of Science ®Google Scholar
• Hui S, Brunstein C, Takahashi Y, et al. Dose escalation of total marrow irradiation in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(7):1110–1116.
   PubMed Web of Science ®Google Scholar
• Patel PR, Rondelli D. Total marrow and lymphoid irradiation to rescue refractory leukemia. Biol Blood Marrow Transplant. 2017;23(4):536–537.
   PubMed Web of Science ®Google Scholar
• Jensen LG, Stiller T, Wong JYC, et al Total marrow lymphoid irradiation/fludarabine/ melphalan conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24(2):301–307.
   PubMed Web of Science ®Google Scholar
• Wong JY, Rosenthal J, Liu A, et al. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2009;73(1):273–279.
   PubMed Web of Science ®Google Scholar
• Wong JY, Liu A, Schultheiss T, et al. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant. 2006;12(3):306–315.
   PubMed Web of Science ®Google Scholar
• Bakr M, Rasheed W, Mohamed SY, et al. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012;18(12):1897–1904.
   PubMed Web of Science ®Google Scholar
• Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104(10):3028–3037.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Jia J, Yue C, et al. Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia. Bone Marrow Transplant. 2018;53(4):438–448.
   PubMed Web of Science ®Google Scholar
• Yeginer M, Roeske JC, Radosevich JA, et al. Linear accelerator-based intensity-modulated total marrow irradiation technique for treatment of hematologic malignancies: a dosimetric feasibility study. Int J Radiat Oncol Biol Phys. 2011;79(4):1256–1265.
   PubMed Web of Science ®Google Scholar
• Zhang R, Shi W, Wang HF, et al. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia. Bone Marrow Transplant. 2017;52(9):1253–1260.
   PubMed Web of Science ®Google Scholar
• Fang J, Zhang R, Wang H, et al. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective comparative study. Leuk Res. 2016;46:61–68.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3):250–259.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–3219.
   PubMed Web of Science ®Google Scholar
• Saadeh SS, Litzow MR. Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state. Expert Rev Hematol. 2018;11(3):195–207.
   PubMed Web of Science ®Google Scholar
• Cahu X, Labopin M, Giebel S, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016;51(3):351–357.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Socie G, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(1):139–149.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Anasetti C, Zhang M-J, et al. Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(4):726–733.
   PubMed Web of Science ®Google Scholar
• Bazarbachi AH, Al Hamed R, Labopin M, et al. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020;55(3):595–602.
   PubMed Web of Science ®Google Scholar
• Hill-Kayser CE, Plastaras JP, Tochner Z, et al. TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant. 2011;46(4):475–484.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Bieri S, Mermillod B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14(2):579–585.
   PubMed Web of Science ®Google Scholar
• Chou RH, Wong GB, Kramer JH, et al. Toxicities of total-body irradiation for pediatric bone marrow transplantation. Int J Radiat Oncol Biol Phys. 1996;34(4):843–851.
   PubMed Web of Science ®Google Scholar
• Mohty M, Malard F, Savani BN. High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink? Biol Blood Marrow Transplant. 2015;21(4):620–624.
   PubMed Web of Science ®Google Scholar
• Shigematsu A, Kondo T, Yamamoto S, et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2008;14(5):568–575.
   PubMed Web of Science ®Google Scholar
• Pasvolsky O, Morelli O, Rozovski U, et al. Anthracycline-induced cardiotoxicity in acute myeloid leukemia patients who undergo allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2019;19(7):e343–e348.
   PubMed Web of Science ®Google Scholar
• Bao Z, Zhao H, Wang D, et al. Feasibility of a novel dose fractionation strategy in TMI/TMLI. Radiat Oncol. 2018;13(1):248–248.
   PubMedGoogle Scholar